英国医疗保健专业人员对英夫利昔单抗和甘精胰岛素生物类似药的知识、态度及实践差异。
Differences in UK healthcare professionals' knowledge, attitude and practice towards infliximab and insulin glargine biosimilars.
作者信息
Aladul Mohammed I, Fitzpatrick Raymond W, Chapman Stephen R
机构信息
School of Pharmacy, Keele University, Keele, UK.
School of Pharmacy, University of Mosul, Mosul, Nineveh, Iraq.
出版信息
Int J Pharm Pract. 2019 Apr;27(2):214-217. doi: 10.1111/ijpp.12485. Epub 2018 Aug 30.
OBJECTIVES
To investigate knowledge and attitudes of different healthcare professionals in UK towards infliximab and insulin glargine biosimilars METHODS: UK medical consultants/registrars, nurses and pharmacists participated in anonymised, self-administered web-based survey distributed by professional associations.
KEY FINDINGS
There were 234 respondents: medical consultants/registrars (150), nurses (58) and pharmacists (26). 76% of medical consultants/registrars, 84% of pharmacists and 53% of nurses understood what biosimilars were. Medical consultants/registrars and pharmacists had safety and efficacy concerns when switching patients compared to initiation. Nurses had similar levels of safety and efficacy concerns about initiation.
CONCLUSION
Healthcare professionals were more comfortable with the initiation of biosimilars than switching current patients. Medical consultants/registrars and pharmacists were more informed than nurses.
目的
调查英国不同医疗保健专业人员对英夫利昔单抗和甘精胰岛素生物类似药的知识及态度。方法：英国医学顾问/住院医师、护士和药剂师参与了由专业协会分发的匿名、自行填写的基于网络的调查。
主要发现
共有234名受访者，其中医学顾问/住院医师150名、护士58名、药剂师26名。76%的医学顾问/住院医师、84%的药剂师和53%的护士了解生物类似药是什么。与起始治疗相比，医学顾问/住院医师和药剂师在转换患者时对安全性和有效性存在担忧。护士对起始治疗的安全性和有效性担忧程度相似。
结论
医疗保健专业人员对生物类似药的起始治疗比对转换现有患者更放心。医学顾问/住院医师和药剂师比护士了解得更多。
Zotero 插件